A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425

Status	RECRUITING
Phase	Phase 2
Sponsor	Apogee Therapeutics, Inc.
Enrollment	350 participants

Key Eligibility Criteria

Inclusion (3)

- Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol
- Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777
- Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study

Exclusion (4)

- Participants who have developed an AE while participating in the Parent Study. which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient
- Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study
- Use of any of the prohibited medications in the Parent Study through Screening Visit (Visit 1) of the LTE study
- Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments

Locations (42 total)

Investigational Site, Fountain Valley, California, United States
Investigational Site, Los Angeles, California, United States
Investigational Site, Coral Gables, Florida, United States
... and 39 more locations